PSG1 FOR USE IN THE TREATMENT OF OSTEOARTHRITIS
The use of Fc-tagged Pregnancy-specific glycoprotein 1 (PSG1-Fc) in a method of treatment of osteoarthritis or damaged cartilage in a human, in which the PSG1 is administered by intra-articular injection, is described. Also described is the use of CC49 in a method of treatment of osteoarthritis or damaged cartilage in an equine mammal, in which the CC49 is administered by intra-articular injection. (Fig. 3A-C) Also described is the use of PSG1 in a method of treatment of wounds, scarring, burns and diabetic ulcers in a mammal..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 21. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MOORE TOM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-21, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 |
|---|
| Patentnummer: |
EP4322984 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA00050422X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA00050422X | ||
| 003 | DE-627 | ||
| 005 | 20240419121929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA00050422X | ||
| 035 | |a (EPA)EP4322984 | ||
| 035 | |a (EPA)75539100 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MOORE TOM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PSG1 FOR USE IN THE TREATMENT OF OSTEOARTHRITIS |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-21, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 | ||
| 520 | |a The use of Fc-tagged Pregnancy-specific glycoprotein 1 (PSG1-Fc) in a method of treatment of osteoarthritis or damaged cartilage in a human, in which the PSG1 is administered by intra-articular injection, is described. Also described is the use of CC49 in a method of treatment of osteoarthritis or damaged cartilage in an equine mammal, in which the CC49 is administered by intra-articular injection. (Fig. 3A-C) Also described is the use of PSG1 in a method of treatment of wounds, scarring, burns and diabetic ulcers in a mammal. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CLOVER ANTHONY JAMES PETERSON |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 21. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75539100/publication/EP4322984A1?q=EP4322984 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 02 | ||